Alisertib is an orally available, investigational, reversible, ATP-competitive, selective aurora A kinase inhibitor. It disrupts mitotic spindle assembly, chromosome segregation, and cell proliferation by inhibiting aurora A kinase.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1028486-01-2
Lycopsamine
pharmaceutical raw material
8-fluoro-6-methoxymoxifloxacin
pharmaceutical raw material
Capmatinib
pharmaceutical raw material
Zelboraf
pharmaceutical raw material
4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid
ZLHFILGSQDJULK-UHFFFAOYSA-N
COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC